Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

28.2K
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
28.2K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

5.7K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.7K
Structure and Function of Platelets01:18

Structure and Function of Platelets

4.0K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
4.0K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

3.5K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.5K
Source And Potency Of Stem Cells01:27

Source And Potency Of Stem Cells

6.5K
Stem cells are undifferentiated cells with extensive self-renewal properties that help them maintain their population during the fetal and adult stages of life. They can specialize in all cell types of the human body. However, their differential potential may vary and can be classified into five types. Stem cells can be (1) Totipotent, (2) Pluripotent, (3) Multipotent, (4) Oligopotent, and (5) Unipotent. Each stem cell has a specific origin; the fertilized egg or zygote is a totipotent cell and...
6.5K
iPS Cell Differentiation01:22

iPS Cell Differentiation

3.2K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Novel platelet pharming using human induced pluripotent stem cells].

Bulletin de l'Academie nationale de medecine·2020
Same author

Early detection of Niemann-pick disease type C with cataplexy and orexin levels: continuous observation with and without Miglustat.

Orphanet journal of rare diseases·2020
Same author

Perirenal fat thickness as a predictor of postoperative complications after laparoscopic distal gastrectomy for gastric cancer.

BJS open·2020
Same author

Morphological lymphocytic reaction, patient prognosis and PD-1 expression after surgical resection for oesophageal cancer.

The British journal of surgery·2019
Same author

Laparoscopic sigmoidectomy and double-stapling technique anastomosis via needlescopic surgery - a video vignette.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2018
Same author

Manipulating megakaryocytes to manufacture platelets ex vivo.

Journal of thrombosis and haemostasis : JTH·2015

Related Experiment Video

Updated: Feb 25, 2026

Generation of Human Induced Pluripotent Stem Cells from Peripheral Blood Using the STEMCCA Lentiviral Vector
12:03

Generation of Human Induced Pluripotent Stem Cells from Peripheral Blood Using the STEMCCA Lentiviral Vector

Published on: October 31, 2012

27.5K

Platelet production from induced pluripotent stem cells.

N Sugimoto1, K Eto1

  • 1Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.

Journal of Thrombosis and Haemostasis : JTH
|July 29, 2017
PubMed
Summary

Induced pluripotent stem cells (iPSCs) offer a promising source for ex vivo platelet production, addressing supply and safety concerns in transfusions. This approach could revolutionize regenerative medicine and blood transfusion systems.

Keywords:
bioreactorsblood plateletsinduced pluripotent stem cellsmegakaryocytestransfusion reaction

More Related Videos

Induced Pluripotent Stem Cell Generation from Blood Cells Using Sendai Virus and Centrifugation
09:57

Induced Pluripotent Stem Cell Generation from Blood Cells Using Sendai Virus and Centrifugation

Published on: December 21, 2016

15.3K
Generation of Integration-free Induced Pluripotent Stem Cells from Human Peripheral Blood Mononuclear Cells Using Episomal Vectors
09:45

Generation of Integration-free Induced Pluripotent Stem Cells from Human Peripheral Blood Mononuclear Cells Using Episomal Vectors

Published on: January 1, 2017

11.5K

Related Experiment Videos

Last Updated: Feb 25, 2026

Generation of Human Induced Pluripotent Stem Cells from Peripheral Blood Using the STEMCCA Lentiviral Vector
12:03

Generation of Human Induced Pluripotent Stem Cells from Peripheral Blood Using the STEMCCA Lentiviral Vector

Published on: October 31, 2012

27.5K
Induced Pluripotent Stem Cell Generation from Blood Cells Using Sendai Virus and Centrifugation
09:57

Induced Pluripotent Stem Cell Generation from Blood Cells Using Sendai Virus and Centrifugation

Published on: December 21, 2016

15.3K
Generation of Integration-free Induced Pluripotent Stem Cells from Human Peripheral Blood Mononuclear Cells Using Episomal Vectors
09:45

Generation of Integration-free Induced Pluripotent Stem Cells from Human Peripheral Blood Mononuclear Cells Using Episomal Vectors

Published on: January 1, 2017

11.5K

Area of Science:

  • Regenerative Medicine
  • Hematology
  • Biotechnology

Background:

  • Current platelet transfusion products face limitations in supply and safety.
  • Induced pluripotent stem cells (iPSCs) are a viable alternative source for platelet production due to their self-renewal and accessibility.
  • Established megakaryocyte (MK) lines from iPSCs offer cryopreservable master cells for Good Manufacturing Practice (GMP)-grade platelet production.

Purpose of the Study:

  • To review the advancements in ex vivo production of human platelets derived from iPSCs.
  • To explore the potential of iPSC-derived platelets in overcoming limitations of current transfusion products.
  • To discuss the clinical applications and future prospects of iPSC-based platelet generation.

Main Methods:

  • Generation of expandable and cryopreservable megakaryocyte (MK) lines from human iPSCs.
  • Utilization of bioreactors mimicking in vivo environments for platelet production.
  • Development of strategies for producing autologous, HLA-compatible, and HLA-deleted platelets.

Main Results:

  • iPSC-derived MKs can be cryopreserved, ensuring on-demand availability and safety.
  • Bioreactor technology and thrombopoiesis-promoting substances enhance platelet production efficiency.
  • Strategies for HLA and HPA manipulation can mitigate alloimmune complications and create universal platelet products.

Conclusions:

  • Ex vivo iPSC-derived platelet production holds the potential to revolutionize the blood transfusion system.
  • HLA-deleted platelets could serve as a universal product for widespread clinical application.
  • This technology is poised to lead advancements in iPSC-based regenerative medicine.